Table 2.
Multivariate survival analysis in HCC patients beyond Milan criteria undergoing surgical resection or transarterial chemoembolization (n = 1303).
| Overall survival | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | CI | p | HR | CI | p | |
| Age (≦66/ > 66 years) | 1.242 | 1.096–1.470 | < 0.001 | 1.145 | 1.004–1.305 | 0.043 |
| Sex (male/female) | 0.975 | 0.834–1.139 | 0.747 | |||
| HBsAg (negative/positive) | 0.918 | 0.810–1.040 | 0.179 | |||
| Anti-HCV (negative/positive) | 0.870 | 0.754–1.003 | 0.055 | |||
| Albumin level (≥ 3.5/ < 3.5 g/dL) | 1.854 | 1.617–2.127 | < 0.001 | |||
| Bilirubin level (≦1.1/ > 1.1 mg/dL) | 1.379 | 1.201–1.582 | < 0.001 | |||
| ALT (≦40/ > 40 IU/L) | 0.917 | 0.808–1.041 | 0.181 | |||
| Creatinine (≦1.1/ > 1.1 mg/dL) | 1.176 | 1.027–1.347 | 0.012 | |||
| Platelet (≥ 150,000/ < 150,000/μL) | 0.912 | 0.802–1.038 | 0.162 | |||
| INR of PT (≦1.0/ > 1.0) | 1.483 | 1.292–1.702 | < 0.001 | |||
| AFP (≦200/ > 200 ng/mL) | 1.693 | 1.491–1.921 | < 0.001 | 1.602 | 1.402–1.831 | < 0.001 |
| Performance status 0–1/2–4 | 1.835 | 1.562–2.156 | < 0.001 | 1.316 | 1.115–1.553 | < 0.001 |
| Tumor burden score | ||||||
| Low | 1 | 1 | ||||
| Medium | 1.215 | 1.040–1.419 | < 0.001 | 1.225 | 1.045–1.436 | 0.012 |
| High | 2.225 | 1.861–2.660 | < 0.001 | 1.976 | 1.637–2.384 | < 0.001 |
| ALBI grade 1/grade2–3 | 1.828 | 1.608–2.079 | < 0.001 | 1.529 | 1.342–1.743 | < 0.001 |
| Vascular invasion (no/yes) | 1.892 | 1.641–2.181 | < 0.001 | 1.568 | 1.354–1.816 | < 0.001 |
| SR versus TACE | 2.494 | 2.181–2.852 | < 0.001 | 2.396 | 2.082–2.759 | < 0.001 |
The forepart of the parentheses was set as the reference group in the univariate and multivariate analysis.
AFP ɑ-fetoprotein, ALBI albumin-bilirubin, ALT alanine aminotransferase, INR of PT international normalized ratio of prothrombin time, SR surgical resection, TACE transarterial chemoembolization, TBS tumor burden score.